These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161 [TBL] [Abstract][Full Text] [Related]
24. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319 [TBL] [Abstract][Full Text] [Related]
30. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Golden JW; Josleyn MD; Hooper JW Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547 [TBL] [Abstract][Full Text] [Related]
31. Animal models of orthopoxvirus infection. Chapman JL; Nichols DK; Martinez MJ; Raymond JW Vet Pathol; 2010 Sep; 47(5):852-70. PubMed ID: 20682806 [TBL] [Abstract][Full Text] [Related]
32. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Rees DG; Gates AJ; Green M; Eastaugh L; Lukaszewski RA; Griffin KF; Krieg AM; Titball RW Antiviral Res; 2005 Feb; 65(2):87-95. PubMed ID: 15708635 [TBL] [Abstract][Full Text] [Related]
33. Co-administration of recombinant major envelope proteins (rA27L and rH3L) of buffalopox virus provides enhanced immunogenicity and protective efficacy in animal models. Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Pandey AB; Shivachandra SB Antiviral Res; 2017 May; 141():174-178. PubMed ID: 28259752 [TBL] [Abstract][Full Text] [Related]
34. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Delaney KN; Phipps JP; Johnson JB; Mizel SB Viral Immunol; 2010 Apr; 23(2):201-10. PubMed ID: 20374000 [TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and protective efficacy of Semliki forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins. Zheng M; Jin N; Liu Q; Huo X; Li Y; Hu B; Ma H; Zhu Z; Cong Y; Li X; Jin M; Zhu G Virology; 2009 Aug; 391(1):33-43. PubMed ID: 19559453 [TBL] [Abstract][Full Text] [Related]
37. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. Hatch GJ; Graham VA; Bewley KR; Tree JA; Dennis M; Taylor I; Funnell SG; Bate SR; Steeds K; Tipton T; Bean T; Hudson L; Atkinson DJ; McLuckie G; Charlwood M; Roberts AD; Vipond J J Virol; 2013 Jul; 87(14):7805-15. PubMed ID: 23658452 [TBL] [Abstract][Full Text] [Related]
38. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. Chen Z; Earl P; Americo J; Damon I; Smith SK; Yu F; Sebrell A; Emerson S; Cohen G; Eisenberg RJ; Gorshkova I; Schuck P; Satterfield W; Moss B; Purcell R J Virol; 2007 Sep; 81(17):8989-95. PubMed ID: 17581986 [TBL] [Abstract][Full Text] [Related]
40. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene. Ibuki K; Funahashi SI; Yamamoto H; Nakamura M; Igarashi T; Miura T; Ido E; Hayami M; Shida H J Gen Virol; 1997 Jan; 78 ( Pt 1)():147-52. PubMed ID: 9010298 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]